Cellatoz Therapeutics - Seongnam

Cellatoz Therapeutics with the goal of resolving the unmet medical needs of incurable diseases. Korea's top R & D specialists gather to discover differentiated therapeutic cell and platform technologies, and promote the commercialization of cell therapy products based on the company's intermediary research and product development capabilities.Cellatoz Therapeutics are the first in the world to acquire musculoskeletal stem cell (MSSC) induction technology capable of final differentiation from embryonic stem cells and inducible pluripotent stem cells (iPSC) into mesodermal tissue cells. By modulating the cell differentiation signals of the cells, we are developing a therapeutic agent for musculoskeletal-related diseases (eg compound fracture, arthritic cartilage damage, etc.) that can regenerate and repair the tissue of the musculoskeletal injured area.